8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 6, 2020)

Filed February 6, 2020For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the fourth quarter and full year ended December 31, 2019, via a press release furnished on February 6, 2020. While the filing itself does not contain detailed financial figures, it directs investors to the press release (Exhibit 99.1) for comprehensive information on the company's operational performance and financial condition. Investors should refer to this press release for specifics regarding revenue, profitability, and other key financial metrics for the period. The filing also includes the interactive data file cover page. It's important to note that the information furnished under Item 2.02 and Exhibit 99.1 is not considered "filed" for regulatory purposes under Section 18 of the Exchange Act, meaning it does not carry the same legal liabilities as a formally filed document. However, it remains a crucial source of timely information for understanding Alnylam's recent performance and outlook.

Key Highlights

  • 1Alnylam Pharmaceuticals announced Q4 and Full Year 2019 financial results on February 6, 2020.
  • 2Key financial and operational details are provided in the furnished press release (Exhibit 99.1).
  • 3Investors should consult Exhibit 99.1 for specific financial performance data.
  • 4The filing includes the Cover Page Interactive Data File.
  • 5Information furnished under Item 2.02 is not "filed" under Section 18 of the Exchange Act.
  • 6This disclosure provides a timely update on the company's financial condition.

Frequently Asked Questions

The detailed financial results for the quarter and year ended December 31, 2019, are available in the press release furnished as Exhibit 99.1 to this Form 8-K filing.

When information is "furnished" under Item 2.02, it is generally for informational purposes and is not subject to the same liabilities as information "filed" under Section 18 of the Securities Exchange Act of 1934. However, it is still considered important information for investors to review.

No, this Form 8-K filing primarily serves to announce the release of the financial results and directs investors to the press release (Exhibit 99.1) for the detailed information. The press release itself contains the specific financial data and commentary.

Investors should review the press release (Exhibit 99.1) to understand the company's revenue growth, profitability, pipeline updates, and any forward-looking statements, which can provide insights into the company's current operational health and future prospects.